🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against superbug strains of the pathogen, according to health experts.

An International Challenge

The sexually transmitted infection are on the rise around the world, with estimates suggesting more than 82 million infections per year. Especially elevated rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary step in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring found that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in recent days for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists believe that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is also used to treat UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a unique collaborative effort for antibiotic development. The charitable organization GARDP partnered with the drug firm Innoviva to see it through.

“This authorization represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Data and Worldwide Availability

Based on data published in a prominent scientific publication, the new drug cured more than 90% of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which involves two antibiotics. The research enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals on the front lines have shared optimism. The availability of a easy-to-administer therapy like this is hailed as a "revolutionary step" for public health efforts. This is considered crucial to reduce the burden of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.